Production (Stage)
Innate Pharma S.A.
IPHA
$2.08
-$0.09-4.15%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -163.39% | -168.69% | -1,525.37% | -1,559.15% | 84.81% |
| Total Depreciation and Amortization | -41.66% | -40.49% | -69.02% | -68.28% | -35.84% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 333.67% | 342.50% | -96.46% | -96.37% | -99.24% |
| Change in Net Operating Assets | 191.73% | 193.58% | 241.93% | 245.30% | -835.82% |
| Cash from Operations | 53.38% | 52.44% | 126.19% | 126.81% | -9.09% |
| Capital Expenditure | -154.87% | -159.39% | 9.45% | 7.30% | 61.56% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -60.07% | -59.26% | 1,806.41% | 1,851.18% | 816.70% |
| Cash from Investing | -60.79% | -60.00% | 474.61% | 483.55% | 868.15% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -488.79% | -488.79% | -177.29% | -177.29% | 28.18% |
| Issuance of Common Stock | 5,931.91% | 5,931.91% | -73.28% | -73.28% | 683.33% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -131.14% | -135.83% | -243.42% | -251.55% | 12.58% |
| Foreign Exchange rate Adjustments | -290.49% | -294.16% | -275.29% | -279.31% | -43.85% |
| Miscellaneous Cash Flow Adjustments | -- | -- | 0.00% | 0.00% | -100.00% |
| Net Change in Cash | -339.84% | -348.69% | 95.25% | 95.14% | 95.45% |